KAIST researchers have discovered that 'DEAD-box helicases 54 (DDX54)', a type of RNA-binding protein, is the master ...

Researchers have discovered that 'DEAD-box helicases 54 (DDX54)', a type of RNA-binding protein, is the master regulator that hinders the effectiveness of immunotherapy -- opening a new path for lung ...

BST1和TMB作为潜在的生物标志物，或许能够帮助更精准地分层治疗。未来需通过更大规模的随机试验验证这些发现，并进一步探索生物标志物以优化 ...

Immune checkpoint inhibitors, a class of immunotherapies that help immune cells attack cancer more effectively, have ...

The companies were showcasing lung cancer data from their two rival blockbuster ... tumour mutation burden (TMB) in its latest studies. The combination tripled progression-free survival at one ...

but it finally has a positive result in lung cancer. In the POSEIDON trial, triple therapy with PD-L1 inhibitor Imfinzi (durvalumab), CTLA4 inhibitor tremelimumab and a choice of chemotherapy ...

A new study shows how the lungs respond to poor diet. For cancers of organs like the liver, the long-term impact of our diet has been well studied -- so much so that we have guidance about red ...

NSCLC is one of the most common types of lung cancer and the leading cause of cancerrelated deaths globally ... The test also reports a Tumor Mutational Burden (TMB) score. The test is intended to be ...

The assay will identify patients with six cancer types, namely solid tumours, breast cancer, colorectal cancer (CRC), melanoma, non-small cell lung cancer ... burden (TMB) from the total nucleic ...